MetaCap

Myriad Genetics (MYGN) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova (TKNO) has outperformed Myriad Genetics (MYGN) over the past year, gaining 77.4% versus a loss of 26.0%. Over five years, TKNO leads with a -63.6% price change compared with -79.5% for MYGN. Myriad Genetics is the larger company by market cap ($523.7 million vs $480.0 million), about 1.1 times the size, while Alpha Teknova is growing revenue faster (+7.4% vs -1.6%).

Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -44.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MYGN-26.02%TKNO+77.44%
+126%+28%-70%
Nov 21, 20251 yearNov 20, 2026
MYGN-80.54%TKNO-69.50%
+6%-47%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MYGN versus TKNO key metrics
MetricMYGNTKNO
Share price$5.46$7.63
Market cap$523.74M$479.95M
1-day change-1.44%-2.30%
YTD return-11.22%+100.79%
1-year return-26.02%+77.44%
5-year return-79.48%-63.63%
EPS (TTM)$-1.35$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$824.50M$40.52M
Revenue growth (YoY)-1.56%+7.35%
Net income (latest FY)$-365.90M$-17.26M
Gross margin69.93%33.17%
Operating margin-46.96%-41.90%
Net margin-44.38%-42.59%
52-week high$8.09$9.48
52-week low$2.74$1.91
Distance from 52-week high-32.51%-19.51%
Analyst consensusholdnone
Avg. price target upside+8.06%+28.83%
Average volume2.26M437.31K
Shares outstanding95.92M62.90M
Employees2,700158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TKNO has outperformed MYGN by 103.5 percentage points over the past year.
  • Alpha Teknova grew revenue faster in its latest fiscal year (+7.35% vs -1.56%).

About Myriad Genetics

MYGN stock →

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

MYGN vs TKNO FAQ

Which is bigger, Myriad Genetics or Alpha Teknova?

Myriad Genetics (MYGN) is larger, with a market capitalization of $523.74M compared with $479.95M for Alpha Teknova (TKNO).

Which stock has performed better over the past year, MYGN or TKNO?

TKNO returned +77.44% over the past 12 months, compared with -26.02% for MYGN (price return, excluding dividends). Past performance does not predict future results.

Are Myriad Genetics and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons